What is IGF-1 LR3 0.1 MG

IGF-1 LR3 0.1 MG is a synthetic, long-acting analogue of human Insulin-like Growth Factor 1 (IGF-1) studied in research for its extreme anabolic properties and ability to induce cellular hyperplasia. It is intended exclusively for research use.

Regarding its chemical identity, IGF-1 has a molecular formula of C400H625N111O115S6 and a molecular weight of 9111.6 g/mol. Its reported canonical sequence is Long [Arg3]-IGF-I (83 amino acids). A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include IGF-1.

Product for research use.

Mechanism of action of IGF-1

IGF-1 LR3 acts by binding to the IGF-1 receptor, triggering intense cellular proliferation, muscle hyperplasia (the creation of new muscle cells), and profound amino acid uptake. It also inhibits cellular apoptosis and promotes nerve regeneration.

Pharmacokinetics and pharmacodynamics of IGF-1

The “LR3” modification (an Arginine substitution at position 3 and a 13-amino-acid extension) prevents the peptide from binding to IGF-Binding Proteins (IGFBPs). This dramatically increases its biological half-life from ~20 minutes (native IGF-1) to 20-30 hours, vastly amplifying its potency.

Scientific evidence on IGF-1

The available evidence on IGF-1 is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in models of severe muscle wasting, burns, and neurological damage. Preclinical models demonstrate unparalleled ability to grow new muscle tissue and repair damaged cells compared to native growth factors.

IGF-1 applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

IGF-1 protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for IGF-1, so no trial schemes or quantities are specified.

The presentations of this product (0.1 MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of IGF-1

As a general guideline for laboratory handling, lyophilized peptides such as IGF-1 are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 0.1 MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

IGF-1 Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented IGF-1 security profile

The documented safety information in open sources for IGF-1 is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Due to its extreme potency and long half-life, systemic administration carries significant theoretical risks of severe hypoglycemia, organomegaly (enlargement of internal organs), and the acceleration of existing tumor growth due to its universal mitogenic effects.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

IGF-1 in a comparative context

Compared to native IGF-1 or IGF-1 DES, LR3 is the longest-acting and most potent systemically. While HGH stimulates the liver to produce native IGF-1, administering IGF-1 LR3 bypasses the liver entirely and delivers a continuously active, unbound growth factor directly to tissues.

History and development of IGF-1

Developed to overcome the severe limitations of native IGF-1, which is rapidly neutralized by binding proteins in the bloodstream. LR3 was designed specifically for laboratory research to provide a stable, highly active molecule for studying tissue growth and cell culture.